Advanced Breast Angiosarcoma Completely Responding to Chemotherapy


Introduction: For patients with anthracycline-resistant metastatic angiosarcoma, currently there is no available standard for second-line therapy and there is a need for novel effective regimens to improve response rates. Case report: We reported here about a case of a primary angiosarcoma of both breasts in a 34-year-old woman presenting lung metastases. At the completion of 3 cycles of the MAID regimen including mesna, adriamycin, ifosfamide and dacarbazine, CT showed progression of the disease (PD). Subsequently second-line chemotherapy was started using GVP regimen consisting of gemcitabine, vincristine and cisplatin. Complete response (CR) of the lung metastases was achieved after 6 treatment cycles. Conclusion: In the absence of an effective therapy among patients with anthracycline-resistant metastatic breast angiosarcoma, a GVP chemo-regimen can be performed as a selective option.

Share and Cite:

Z. Luo, Q. Wang, W. Peng, J. Chang, X. Hu and X. Hong, "Advanced Breast Angiosarcoma Completely Responding to Chemotherapy," Journal of Cancer Therapy, Vol. 4 No. 4, 2013, pp. 811-814. doi: 10.4236/jct.2013.44092.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. M. Donnell, P. P. Rosen, P. H. Lieberman, et al., “Angiosarcoma and Other Vascular Tumors of the Breast,” American Journal of Surgical Pathology, Vol. 5, 1981, pp. 629-642. doi:10.1097/00000478-198110000-00005
[2] A. Luini, G. Gatti, J. Diaz, et al., “Angiosarcoma of the Breast: The Experience of the European Institute of Oncology and a Review of the Literature,” Breast Cancer Research and Treatment, Vol. 105, No. 1, 2007, pp. 81-85. doi:10.1007/s10549-006-9429-z
[3] K. T. Chen, D. D. Kirkegaard and J. J. Bocian, “Angiosarcoma of the Breast,” Cancer, Vol. 46, No. 2, 1980, pp. 368-371. doi:10.1002/1097-0142(19800715)46:2<368::AID-CNCR2820460226>3.0.CO;2-E
[4] S. A. Zhou, H. Wei and K. Ding, “A Rare Case of Metachronous Bilateral Angiosarcoma of the Breast,” Breast Care (Basel), Vol. 4, No. 6, 2009, pp. 405-407. doi:10.1159/000261506
[5] M. J. Merino, D. Carter and M. Berman, “Angiosarcoma of the Breast,” American Journal of Surgical Pathology, Vol. 7, No. 1, 1983, pp. 53-60. doi:10.1097/00000478-198301000-00005
[6] M. Van Glabbeke, A. T. van Oosterom, J. W. Oosterhuis, et al., “Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2185 Patients Treated with Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study,” Journal of Clinical Oncology, Vol. 17, 1999, pp. 150-157.
[7] T. Sher, B. T. Hennessy, V. Valero, et al., “Primary Angiosarcomas of the Breast,” Cancer, Vol. 110, No. 1, 2007, pp. 173-178. doi:10.1002/cncr.22784
[8] P. P. Rosen, M. Kimmel and D. Ernsberger, “Mammary Angiosarcoma. The Prognostic Significance of Tumor Differentiation,” Cancer, Vol. 62, No. 10, 1988, pp. 2145-2151. doi:10.1002/1097-0142(19881115)62:10<2145::AID-CNCR2820621014>3.0.CO;2-O
[9] L. R. Silverman, L. Deligdisch, J. Mandeli, et al., “Chemotherapy for Angiosarcoma of the Breast: Case Report of 30-Year Survival and Analysis of the Literature,” Cancer Investigation, Vol. 12, No. 2, 1994, pp. 145-155. doi:10.3109/07357909409024870
[10] K. M. Skubitz and P. A. Haddad, “Paclitaxel and Pegylated-Liposomal Doxorubicin are Both Active in Angiosarcoma,” Cancer, Vol. 104, No. 2, 2005, pp. 361-366. doi:10.1002/cncr.21140
[11] J. T. Hartmann and S. Patel, “Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma,” Drugs, Vol. 65, No. 2, 2005, pp. 167-178. doi:10.2165/00003495-200565020-00002
[12] R. Isogai, A. Kawada, Y. Aragane, et al., “Successful Treatment of Pulmonary Metastasis and Local Recurrence of Angiosarcoma with Docetaxel,” Journal of Dermatology, Vol. 31, No. 4, 2004, pp. 335-341.
[13] M. L. Hensley, R. Maki, E. Venkatraman, et al., “Gemcitabine and Docetaxel in Patients with Unresectable Leiomyosarcoma: Results of a Phase II Trial,” Journal of Clinical Oncology, Vol. 20, No. 12, 2002, pp. 2824-2831. doi:10.1200/JCO.2002.11.050
[14] S. Okuno, J. Edmonson, M. Mahoney, et al., “Phase II trial of Gemcitabine in Advanced Sarcomas,” Cancer, Vol. 94, No. 12, 2002, pp. 3225-3229. doi:10.1002/cncr.10602
[15] S. R. Patel, V. Gandhi, J. Jenkins, et al., “Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation,” Journal of Clinical Oncology, Vol. 19, No. 15, 2001, pp. 3483-3489.
[16] K. M. Leu, L. J. Ostruszka, D. Shewach, et al., “Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment with Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma,” Journal of Clinical Oncology, Vol. 22, No. 9, 2004, pp. 1706-1712. doi:10.1200/JCO.2004.08.043
[17] A. Minchom, R. L. Jones, C. Fisher, et al., “Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma,” Sarcoma, 2010, Article ID: 264360.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.